Cargando…

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents

Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase which has completed clinical trials for patients with rheumatoid arthritis. In clinical studies fostamatinib treatment was associated with a small elevation of systemic arterial blood pressure (BP), a similar fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lengel, Dave, Lamm Bergström, Eva, Barthlow, Herb, Oldman, Karen, Musgrove, Helen, Harmer, Alex, Valentin, Jean-Pierre, Duffy, Paul, Braddock, Martin, Curwen, Jon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618647/ https://www.ncbi.nlm.nih.gov/pubmed/26516588 http://dx.doi.org/10.1002/prp2.176

Ejemplares similares

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib
por: Rolf, Michael G, et al.
Publicado: (2015)

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
por: Harbi, Maan H., et al.
Publicado: (2022)

Immediate Prescription of Oral Antihypertensive Agents in Hypertensive Urgency Patients and the Risk of Revisits with Elevated Blood Pressure
por: Sricharoen, Pungkava, et al.
Publicado: (2020)

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
por: Matsukane, Ryosuke, et al.
Publicado: (2022)

Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib
por: Innao, Vanessa, et al.
Publicado: (2023)

Appropriateness of Bolus Antihypertensive Therapy for Elevated Blood Pressure in the Emergency Department
por: Miller, Joseph B., et al.
Publicado: (2017)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib
por: Cooper, Nichola, et al.
Publicado: (2021)

P1614: TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB
por: Mingot-Castellano, María Eva, et al.
Publicado: (2023)

Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
por: Tabassum, Neha, et al.
Publicado: (2020)

The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Chen, Yuehong, et al.
Publicado: (2021)

Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion
por: Lucchesi, Alessandro, et al.
Publicado: (2023)

Initial antihypertensive agent effects on acute blood pressure after intracerebral haemorrhage
por: Ng, Yisi, et al.
Publicado: (2022)

Neoplasm Risk in Patients With Rheumatoid Arthritis Treated With Fostamatinib: A Systematic Review and Meta-analysis
por: Chen, Yuehong, et al.
Publicado: (2022)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023)

P1613: REAL-WORLD USE OF FOSTAMATINIB IN FRANCE. INTERIM RESULTS OF A NATIONAL REGISTRY.
por: Moulis, Guillaume, et al.
Publicado: (2023)

Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?
por: Hedna, Khedidja, et al.
Publicado: (2015)

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
por: Bussel, James B., et al.
Publicado: (2019)

Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic
por: Strich, Jeffrey R, et al.
Publicado: (2020)

Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
por: Saha, Sovan, et al.
Publicado: (2022)

Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration
por: Wang, Mingyao, et al.
Publicado: (2022)

Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
por: Kuter, David J., et al.
Publicado: (2022)

Is Use of Multiple Antihypertensive Agents to Achieve Blood Pressure Control Associated with Adverse Pregnancy Outcomes?
por: Allen, Sarah E., et al.
Publicado: (2017)

Cognition and drug adherence to oral hypoglycemic and antihypertensive agents in older adults
por: Bakouni, Hamzah, et al.
Publicado: (2019)

Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Kang, Yaqi, et al.
Publicado: (2019)

Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series
por: Hughes, David M., et al.
Publicado: (2021)

The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series
por: Liu, Jessica, et al.
Publicado: (2022)

Retrospective evaluation of labetalol as antihypertensive agent in dogs
por: Zublena, Francesco, et al.
Publicado: (2020)

Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease
por: Weaver, Donald J., et al.
Publicado: (2020)

Blood Pressure Variability as a Risk Factor for Cardiovascular Disease: Which Antihypertensive Agents Are More Effective?
por: de la Sierra, Alejandro
Publicado: (2023)

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies
por: Martin, P., et al.
Publicado: (2016)

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials
por: Bussel, James, et al.
Publicado: (2018)

Eco-Friendly UPLC–MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats
por: Ezzeldin, Essam, et al.
Publicado: (2021)

561. Phase 3 Trial of Fostamatinib for the Treatment of COVID-19: Repurposing an Immunomodulatory Drug Previously Approved for Immune Thrombocytopenia
por: Mallat, Ziad, et al.
Publicado: (2021)

Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature
por: Schiffrin, Ernesto L
Publicado: (2010)

Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions
por: Canoy, D., et al.
Publicado: (2021)

Systolic Blood Pressure Variability When Transitioning From Intravenous to Enteral Antihypertensive Agents in Patients With Hemorrhagic Strokes
por: Alshaya, Abdulrahman I., et al.
Publicado: (2022)

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
por: Herman, SEM, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6skouaq7prir4qmr394iegndp8